Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Negin Allahyari, Saeed Eslami Hasan Abadi, Arezoo Akbarian, Mahnaz Amini, Alireza Bari, Sepideh Hasanzadeh, Sajad Ataei Azimi, Maryam Emadzadeh, Neda Saeedian, Mohammad Moeini Nodeh, Zahra Javidarabshahi, Hossein Rahimi, Mojtaba Abrishami, Mostafa Kamandi, Parisa Ataei, Mohsen Seddigh-Shamsi, Zahra Mozaheb, Alireza Sedaghat, Abolghasem Allahyari, Mahnaz Mozdourian, Mahmoud Mahmoudi, Shahram Amini, Saeid Amel Jamehdar
Publikováno v:
International Immunopharmacology
Highlights • Convalescent plasma (CP) improves outcomes and decrease mortality rate in COVID-19. • CP seems to be most beneficial for treating severe COVID-19 with mild ARDS. • Early administration of CP could contribute to the treatment of sev
Autor:
Seyed Mohammadreza Hashemian, Jalal Heshmatnia, Mihan Pourabdollah Toutkaboni, Payam Tabarsi, Sahar Yousefian, Sara Haseli, Farzaneh Dastan, Hamidreza Jammati, Alireza Dastan, Mohsen Sadeghi, Arda Kiani, Ali Saffaei, Parvaneh Baghaei, Jamshid Salamzadeh, Mohammad Varahram, Zahra Abtahian, Seyed Alireza Nadji, Sharareh Seifi, Alireza Eslaminejad, Majid Marjani, Afshin Moniri, Atefeh Abedini
Publikováno v:
International Immunopharmacology
Highlights • The pathophysiology of severe SARS-CoV-2 infection may be attributed to cytokine release syndrome. • In this syndrome, inflammatory cytokines (especially interleukin 6) are released after the activation of the inflammatory cascade.
Publikováno v:
International Immunopharmacology
Highlights • NCD4LR will contribute to the prediction of NCT in COVID-19 patients. • Patients in the high NCD4LR group had a longer NCT. • NCD4LR show better predictive value than NLR in predicting NCT. • NCD4LR is a potential biomarker for c
Autor:
Negar Khalili, Mohamad Amin Pourhoseingholi, Ilad Alavi Darazam, Azam Soleymaninia, Latif Gachkar, Akram Hoseyni Kusha, Mohammad Mahdi Rabiei, Minoosh Shabani, Legha Lotfollahi, Mahdi Amirdosara, Firouze Hatami, Parham Torabinavid, Omid Moradi, Mohammadreza Hajiesmaeili, Ali Khoshkar, Masoud Mardani, Hadiseh Shabanpour Dehbsneh, Maryam Taleb Shoushtari, Omidvar Rezaei, Seyed Sina Naghibi Irvani, Shervin Shokouhi, Farid Javandoust Gharehbagh
Publikováno v:
International Immunopharmacology
Introduction The effectiveness of umifenovir against COVID-19 is controversial; therefore, clinical trials are crucial to evaluate its efficacy. Methods The study was conducted as a single-center, randomized, open-label clinical trial. Eligible moder
Autor:
Mustafa Saadi Mohammed, Rundk Ahmed Hwaiz, Harmand Ali Hama, Mohammed Merza, Shirin HamaSalih, Badraldin Hamad
Publikováno v:
International Immunopharmacology
SARS-CoV-2 or Coronavirus disease 2019 (COVID-19) outbreak which caused by the severe acute respiratory syndrome, has rapidly spread over the world. The exact mechanism how this virus will affect the liver remained elusive. The aim of this study was
Autor:
Behnaz Bouzari, Hossein Keyvani, Sajad Karampoor, Farhad Zamani, Mohammad Farahmand, Hossein Ajdarkosh, Alireza Tabibzadeh, Hamid Zahednasab, Mehdi Nikkhah, Rasoul Mirzaei, Melika Razavi Hashemi, Azadeh Laali
Publikováno v:
International Immunopharmacology
A cell-surface heparan proteoglycan called Syndecan-1 (SDC-1) has multiple roles in healthy and pathogenic conditions, including respiratory viral infection. In this study, we explore the dynamic alternation in the levels of SDC-1 in cases with COVID
Publikováno v:
International Immunopharmacology
Objective Re-positivity of SARS-CoV-2 in discharged COVID-19 patients have been reported; however, early risk factors for SARS-CoV-2 re-positivity evaluation are limited. Methods This is a prospective study, a total of 145 COVID-19 patients were trea
Publikováno v:
International Immunopharmacology
Background The differences in the characteristics and main causes of critical COVID-19 infection in non-elderly and elderly severe patients remain unknown. Methods We included 273 adult patients with confirmed severe COVID-19 from Tongji Hospital, Wu
Autor:
Ayfer Colak, Veli Iyilikci, Zeynep Altın, Inanc Karakoyun, Nisel Yilmaz, Melda Turken, Sukran Kose, Fatma Demet Arslan
Publikováno v:
International Immunopharmacology
Highlights • COVID-19 is more severe in older patients. • Hypertension is the most frequent comorbidity in severe and non-severe COVID-19 cases. • Cough is the prominent clinical symptom in severe and non-severe COVID-19 cases. • Detection of
Publikováno v:
International Immunopharmacology
Highlight: • DPP-4 inhibition reduced CD4+T cells infiltration and ameliorated insulitis. • DPP-4 inhibition downregulated serum IL-1β and IL-12. • LPS increased CD11b+ cells to infiltrate into islets.
Dipeptidyl-peptidase 4 (DPP-4) inhib
Dipeptidyl-peptidase 4 (DPP-4) inhib